Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODIGY-2: Personalized vs Fixed 177Lu-PSMA-617 in mCRPC
NCT06943495Phase 1Recruiting
- Start
- Aug 2025
- Primary completion
- Mar 2029
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC) (2 arms). Primary endpoints: Administered activity of 177Lu-PSMA-617 up to 36 weeks and Number of participants with subacute adverse events of special interest up to 36 weeks. Started Aug 2025; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06943495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06943495.